Результаты поиска

Bispecific antibodies: unleashing a new era in oncology treatment.

Advancements in diagnostic and therapeutic standards have substantially enhanced the survival of patients with malignant tumors. Nevertheless, the quest for effective strategies to address resistant or recurrent advanced tumors remains a critical and unwavering objective. Bispecific antibodies (BsAbs) unleashed a new era of anti-tumor treatment by simultaneously binding to two distinct targets, thereby enhancing specificity, minimizing off-target toxicities, and synergistically modulating anti-tumor immunity and the tumor microenvironment. Compared with the combination of two monoclonal antibo

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size.

Synchronous diagnosis of acute myeloid leukemia (AML) and symptomatic multiple myeloma (MM) is a rare situation that poses serious therapeutic difficulties. We report the case of a 68-year-old male which evolved simultaneously to symptomatic MM and AML. Both diseases first responded to treatment for 40 months after 7+3 induction and maintenance therapy of azacytidine + lenalidomide. MM relapsed first and was treated with azacytidine + daratumumab, which led an additional 15 months of progression-free survival. Little myeloid clonal size reduction over time was seen. This case shows that AML an

An Integrated Health-System Specialty Pharmacy Model for Coordinating Transitions of Care: Specialty Medication Challenges and Specialty Pharmacist Opportunities.

Adherence and persistence to specialty medications are necessary to achieve successful outcomes of costly therapies. The increasing use of specialty medications has exposed several unique barriers to certain specialty treatments' continuation. Integrated specialty pharmacy teams facilitate transitions in sites of care, between different provider types, among prescribed specialty medications, and during financial coverage changes. We review obstacles encountered within these types of transitions and the role of the specialty pharmacist in overcoming these obstacles. Case examples for each type

SFRP5 inhibits melanin synthesis of melanocytes in vitiligo by suppressing the Wnt/β-catenin signaling.

Secreted frizzled-related protein 5 (SFRP5) plays a pivotal role in regulating the development of many tissues and organs, however, as an inhibitor of Wnt signaling, the role of SFRP5 in vitiligo remains unknown. Hence, we speculated that SFRP5 might be associated with melanogenesis in melanocytes by regulating Wnt signaling in vitiligo. In this study, we found that SFRP5 was overexpressed in the skin lesions of patients with vitiligo. Compared with that in normal epidermal melanocytes (PIG1), the expression of SFRP5 was increased in vitiligo melanocytes (PIG3V). To investigate the effect of S

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.

AbstractPatient-reported outcomes (PROs) give direct insights into the treatment's impact on patient's life and complement clinical outcomes. However, since the advent of chimeric antigen receptor T-cell therapy (CAR-T), PROs have been underreported. Particularly, little is known about long-term health-related quality of life (HRQoL) and dimensions such as mental- and social well-being, working life, and financial burden. Therefore, we evaluated multidimensional PROs in a cross-sectional study among European patients who received CAR-T for hematologic malignancies. Patients completed validated

Связанный с лекарствами остеонекроз челюсти у нескольких пациентов миэломы: серия случаев.

Остеонекроз челюсти (MRONJ), связанный с лекарственными препаратами, является осложнением антирепрессивной и антиангиогенной терапии, используемой при лечении злокачественных заболеваний, и может вызывать значительную функциональную и эстетичную заболеваемость у пациентов. Множественная миелома (ММ) — гематологическая порча плазмы и клеток, часто связанная с остеолитической болезнью костей. Антирезорптивная терапия (АРТ) уменьшает связанные со скелетом явления в MM и других магнатах с участием скелета, но связана с повышенным риском заболевания MRONJ. В настоящем документе представлены клиниче

Editorial: Chimeric antigen receptor T cell therapies and bispecific antibodies in hematologic malignancies.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Advances in the use of ECMO in oncology patient.

BackgroundOver the past decade, ECMO has provided temporary cardiopulmonary support to an increasing number of patients, but the use of extracorporeal membrane oxygenation (ECMO) to provide temporary respiratory and circulatory support to adult patients with malignancy remains controversial.ObjectivesThis paper reviews the specific use of extracorporeal membrane oxygenation (ECMO) in oncology patients.MethodsWe searched PubMed, CINAHL, Cochrane Library, and Embase databases for studies on the use of ECMO in cancer patients between 1998 and 2022. Twenty-four retrospective, prospective, and case

Immune mechanism of low bone mineral density caused by ankylosing spondylitis based on bioinformatics and machine learning.

Background and Objective: This study aims to find the key immune genes and mechanisms of low bone mineral density (LBMD) in ankylosing spondylitis (AS) patients. Methods: AS and LBMD datasets were downloaded from the GEO database, and differential expression gene analysis was performed to obtain DEGs. Immune-related genes (IRGs) were obtained from ImmPort. Overlapping DEGs and IRGs got I-DEGs. Pearson coefficients were used to calculate DEGs and IRGs correlations in the AS and LBMD datasets. Louvain community discovery was used to cluster the co-expression network to get gene modules. The modu

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025.

CAR-T cell therapy has dramatically changed the treatment paradigm for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, there is a notable paucity of comprehensive bibliometric analyses within this specialized domain. On January 26, 2026, publications on CAR-T cell therapy for MM (2013-2025) were retrieved from the Web of Science Core Collection using: TS = (CAR-T OR "chimeric antigen receptor T*" OR "chimeric antigen receptor modified T" OR "chimeric antigen receptor engineered T" OR "chimeric antigen receptor transduced T" OR "chimeric antigen receptor redirected T") AND TS = ("m

Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series.

Patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) following autologous stem cell transplant (ASCT) remain a management challenge with few reliably effective treatments. Lenalidomide, an immunomodulatory drug approved for patients with myelodysplastic syndrome with del(5q), multiple myeloma, and mantle cell lymphoma, has demonstrated some activity in patients with R/R cHL, though the toxicity of traditional doses and schedules has been a barrier to consistent use. Low dose continuous (LDC) schedules have emerged as promising, with a more favorable safety profile. We re

Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.

Baseline risk factors for acute kidney injury (AKI) during chimeric antigen receptor T-cell (CAR-T) therapy are not well described. Hence, we evaluated the incidence and risk factors associated with AKI among patients undergoing CAR-T for relapsed/refractory large B-cell lymphoma. Among 155 patients, 28 (18%) developed AKI with a median time-to-peak creatinine from CAR-T of 9.5 days (range = 3-30). Aetiologies included volume depletion (n = 20, 71%), cytokine release syndrome (n = 5, 18%), nephrotoxins (n = 5, 18%), tumour lysis syndrome (n = 1, 4%) and multifactorial (n = 6, 21%). On univaria

Цитоплания и инфекция после цитакабагена автолейкеля в сильно обработанном реанимированном или рефрактном миеломе.

В феврале Управление по контролю за продуктами питания и лекарственными препаратами одобрило автолекцию Ciltaakabtagene (cilta-cel). 2022 для лечения повторной/реактивной множественной миэломы после four циклы терапии. По поводу CARTITUDE-1 в ходе судебного разбирательства, ≥3 Широко распространены цитопентия и инфекции. Здесь мы пытались охарактеризовать цитопению и инфекцию после вливания цита-села в стандартную систему ухода. Это многоцентральное, ретроспективное исследование включало 105 - пациенты, получившие цилта-сел; 91 Днем 90 и 49 Днем 180 о последующей деятельности. Класс должности

CAR T-Cells in Multiple Myeloma Are Ready for Prime Time.

The survival of patients with multiple myeloma (MM) has been dramatically improved in the last decade thanks to the incorporation of second-generation proteasome inhibitors (PI), immunomodulatory drugs (IMID), and, more recently, anti-CD38 monoclonal antibodies (MoAb). Nevertheless, still, a major proportion of MM patients will relapse, underscoring the need for new therapies in this disease. Moreover, survival in patients failing the current standard of care regimens (including PI, IMIDs, and anti-CD38 MoAb), which is now defined as triple-class refractory, remains dismal, and new drugs with

Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients.

Background/Objectives: Immune effector cell-associated hematotoxicity (ICAHT) is a frequent adverse event after chimeric antigen receptor (CAR)-T cell therapy. Grade ≥ 3 thrombocytopenia occurs in around one-third of patients, and many of them become platelet transfusion-dependent. Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) able to accelerate megakaryopoiesis, which has been used successfully in patients with bone marrow failure and immune thrombocytopenia (ITP). Its role in managing thrombocytopenia and other cytopenias in CAR-T cell-treated patients has been scarcely addressed

Совпадение в полном тексте источника
… Patients were followed from apheresis, including bridge therapy and lymphodepletion until the date of the end of follow-up, regardless of whether transfusion independence was achieved. Figure 1 Flowchart diagram of the study and patients finally enrolled. … therapy: | 30/38 (78.9) Type | R-GEMOX | 12/30 (40.0) R-GDP | 6/30 (20.0) BR | 3 */30 (10.0) R-ICE | 1/30 (3.3) Polatuzumab and BR | 1/30 (3.3) R-ESHAP | 1/30 (3.3) Inotuzumab | 1/30 (3.3) R-MINE | 1/30 (3.3) Radiotherapy | 1/30 (3.3) R-MTX | 1/30 (3.3) Burkimab | 1/30 (3.3) Several strategies | 1/ …

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.

Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class exposed, relapsed and refractory multiple myeloma (RRMM) in the phase 2 KarMMa (Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma) trial. We assessed health-related quality of life (HRQoL) among KarMMa patients. The European Organization for Research and Treatment of Cancer Quality of Life C30 Questionnaire and its supplementary 20-item multiple myeloma module, as well as the Eur

2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery.

MAJOR UPDATES TO 1991 NATIONAL INSTITUTES OF HEALTH GUIDELINES FOR BARIATRIC SURGERY: Metabolic and bariatric surgery (MBS) is recommended for individuals with a body mass index (BMI) >35 kg/m2, regardless of presence, absence, or severity of co-morbidities.MBS should be considered for individuals with metabolic disease and BMI of 30-34.9 kg/m2.BMI thresholds should be adjusted in the Asian population such that a BMI >25 kg/m2 suggests clinical obesity, and individuals with BMI >27.5 kg/m2 should be offered MBS.Long-term results of MBS consistently demonstrate safety and efficacy.Appropriately

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Therapeutic antibodies have revolutionized hematology, offering targeted and effective treatments for both malignant and non-malignant diseases. In hematologic malignancies, anti-CD20, anti-CD19, anti-CD38, and anti-B-cell maturation antigen (BCMA) antibodies have markedly improved survival outcomes, whereas antibody-drug conjugates and bispecific antibodies continue to expand therapeutic possibilities. Besides cancer, complement inhibitors such as eculizumab, ravulizumab, and the recently approved crovalimab have redefined paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic synd

Терапевтический потенциал зубных мезенхимальных стволовых клеток в сравнении с мезенхимальными стволовыми клетками из других источников: систематический обзор исследований животных.

ЦЕНТРАЛЬНАЯ терапия на основе стволовых клеток, являющаяся одной из важнейших областей регенеративной медицины, направлена на совершенствование механизмов ремонта тела (d) путем стимулирования, модуляции и регулирования внутренних стволовых клеток или пополнения пулов клеток, способствуя тем самым развитию гомеостаза и регенерации тканей и предлагая перспективное лечение многочисленных системных заболеваний. В настоящем систематическом обзоре содержится всеобъемлющее резюме исследований животных, в ходе которых изучается эффективность зубоврачебных мезенхимальных стволовых клеток (НКЦ) в лечен

Endoscopic transpapillary gallbladder drainage for the management of acute calculus cholecystitis patients unfit for urgent cholecystectomy.

ObjectivesEndoscopic transpapillary gallbladder drainage (ETGBD) has been proposed as an alternative to surgery or percutaneous cholecystostomy in patients with acute calculus cholecystitis (ACC). We aimed to evaluate the safety and efficacy of ETGBD via endoscopic transpapillary gallbladder stenting (ETGBS) or endoscopic naso-gallbladder drainage (ENGBD) as either a bridging or a definitive treatment option for patients with ACC when a cholecystectomy is delayed or cannot be performed.MethodsFrom July 2014 to December 2018, 171 patients with ACC in whom ETGBD were attempted were retrospective